Many chemotherapeutic agents used for many types of tumors are often associated with severe adverse events and reactions that compromise the effectiveness of chemotherapy treatments. The prediction of the toxicity of treatment and ablity to adjust the dose according to the metabolism of each patient currently allows different therapy schemes.
Some genetic variations have been associated with toxicity in patients treated with fluoropyrimidines (5-FU, Capecitabine), oxaliplatin, irinotecan and other chemotherapeutic agents complexes. There has been a demonstrated association with different degrees of toxicity and validation between genetic polymorphism in DPYD, MTHFR, UGT1A1, TYMS, ERCC1, RRM1 and more genes.
Biomakers has molecular studies of these polymorphisms to predict toxicity to chemotherapy and allow both proper selection of therapeutic regimens and proper adjustment of the dose.